The advanced glycation end product (AGE) inhibitor Pyridorin (pyridoxamine dihydrochloride) has potential in treating diabetic nephropathy, researchers reported here November 1 at the 35th Annual Meeting of the American Society of Nephrology (ASN).
Dr. Thorsten P. Degenhardt and colleagues from BioStratum Incorporated, in Durham, North Carolina, United States, conducted a randomised, placebo-controlled trial including 12 patients with type 2 diabetes and macroalbuminuria greater than 300 mg/day.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!